Nureca Limited — Interim / Quarterly Report 2023

Nov 11, 2022

NURECA

www.nureca.com

Dated-11.11.2022

BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA LIMITED Corporate Relations Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5[th ] Floor, Plot no. C/1 Dalal Street, Fort G Block, Sandra Kurla Complex, Sandra (E} Mumbai-400001 Mumbai-400051 Scrip code: 543264 Scrip Code: NURECA

Subjec: Outcome of Board Meeting under Regulation 30 and 33 of SEBI {Listing Obligations and Disclosure Requirements} Regulations. 2015

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at the Meeting held today i.e. November 11, 2022 (Friday} have -

1. Approved the unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2022.

Copies of the unaudited Standalone and Consolidated Financial Results along with Limited Review Reports from the Company's Statutory Auditors are enclosed herewith.

2. Approved the amendment in the Company's "Code of Conduct for Prevention of Insider Trading" to align the same with the amendment in the SEBI (Prohibition of Insider Trading) Regulations. The amended Code of Conduct for Prevention of Insider Trading will be available on the website of the Company (www.nureca.com).

Presentation on financial results for the quarter and half-year ended September 30, 2022 is also enclosed.

The Board Meeting commenced at 5:00 PM and concluded at 6:30 P.M.

This is for your kind information and records please.

Thanking You,

Yours Sincerely, F 1. ;;J: ��:: (Chetna Anand) Company Secretary & Compliance Officer

NURECA LIMITED

Correspondence Office : SCO 6�7-8, 1st Floor. Madhya Marg, Sector 9-D, Chandigarh 160009 Registered Office: 101 Office Number, Udyog Bhavan, 1st Floor, Sonawala Lane, Goregaon East, Mumbai City ,Maharashtra.- 400063.

Phone No. +91-172-5292900 CJN L24304MH2016PLC320868 . . .

NURECA

www.nureca.com

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: ww .nureca.com Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

		Statement of Unaudited Standalone Financial	Statement of Unaudited Standalone Financial	Results for the quarter and half year ended 30 September 2022	Results for the quarter and half year ended 30 September 2022	Results for the quarter and half year ended 30 September 2022
				Quarter ended		Halfvear ended		Year ended
Sr.	No.	Particulars	30 Septem her 2022 (Unaudited)	30June 2022 (Unaudited)	30 Septem her 2021 (Unaudited)	30 Septem her 2022 (Unaudited)	30 Septem her 2021 (Unaudited)	31 March 2022 (Audited)
I		Revenue fom operations	367.86	260.60	469.10	628.46	1,663.92	2,555.49
2		Other income	19.13	11.75	21.21	30.88	42.60	77.20
3		Total income (1 +2)	386.99	272.35	490.31	659.34	1,706.52	2,632.69
4		Expenses
		Purchae of stock-in-trade	132.25	126.98	502.54	259.23	999.32	1,595.34
		Chages in inventories of stock-in-trade Employee benefts expense Finace costs Depreciation ad amortization expense	143.64 48.52 0.99 6.00	48.38 41.89 1.29 5.90	(222.06) 22.87 1.24 3 02	192.02 90.41 2.28 11.90	(224.41) 47.99 3.41 4.48	(269.16) 98.31 7.31 14.32
		Other expenses	91.87	98.29	105.09	190.16	309.97	573.27
		Total expenses	423.27	322.73	412.70	746.00	1,140.76	2,019.39
5		(Loss)/proft befre income tax (3-4)	(36.28)	(50.38)	77.61	(86.66)	565.76	613.30
6		Tax expense
		- Curent ta - Defrred ta (credit)/chage	(8.44)	(11.71)	22.18 0.57	(20.15)	149.69 (0.32)	155.70 4.51
7		Net (loss)/prof afer income tax (5-6)	(27.84)	(38.67)	54.86	(66.51)	416.39	453.09
8		Other comprehensive income/(expense)
A		(i) Item that will not be recla ifed to proft or loss (ii) Income ta relating to items that will not be reclassifed to proft or loss	0.48 (0.12)	0.48 (0.12)	0.07 (0.02)	0.96 (0.24)	0.10 (0.03)	1.90 (0.48)
B		(i) Item that will be recla ifed to proft or loss (ii) Income ta relating to items that will be recla ifed to proft or loss	- -		-			-
9		Total comprehensive (loss)/income for the period/ year	(27.48)	(38.31)	54.91	(65.79)	416.46	454.51
		(7+8)
JO		(Loss)/earnings per share of Rs. 10 each - Basic ad diluted (in rpees) (not a ualized)	(2.78)	(3.87)	5.49	(6.65)	41.64	45.31
II		Paid-up equity share capital	100.00	100.00	100.00	100.00	100.00	100.00
		(Face value of share - Rs. IO each)
12		Reserve (excluding revaluation resere)						1,937.43
		See accompaying notes to the unaudited stadalone fnacial results

==> picture [125 x 80] intentionally omitted <==

==> picture [562 x 83] intentionally omitted <==

NURECA

www.nureca.com

NURECA LIMITED

		NURECA LIMTED	NURECA LIMTED
		Ofce Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India
		Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com
		Corporate Identifcation Number: L24304MH2016PLC320868
			(mount in I million, unless otherise stated
		Statement of Standalone Assets and Liabilities
				As at
Sr.No.		Particulars	30	September 2022	31 March 2022
				(Unaudited)	(Audited)
	Assets
(I)	Non-current assets
	Proper, plat ad equipment			29.66	32.68
	Right-of-use assets			35.12	41.19
	Intagible assets Intagible a ets under development Finacial a ets			26.76	23.92 4.23
	- Investents			30.56	13.06
	-Loas			13.40
	- Other fnacia assets			2.70	22.14
	Defred ta a ets (net)			21.16	1.01
	lncom ta a ets (net)			15.70	-
	Total non-current assets			175.06	138.23
(2)	Current assets
	Inventories			442.31	631.66
	Finacia1 assets
	- Investments			526.37	331.86
	- Trade receivables			34.53	28.68
	- Cash ad cash equivalents			6.96	81.58
	- Bank balaces other tha cah and cash equivalents			739.44	760.28
	- Other fnacia assets			70.84	67.38
	Other current assets			130.43	155.68
	Total current assets			1,950.88	2,057.12
	Total assets (1+2)			2 125.94	2,195.35
(I)	Equity
	Equity shae capital			I00.00	100.00
	Other equit			1,871.64	1,937.43
	Total equity			1,971.64	2,037.43
(2)	Non- current liabilities
	FinaciaJ liabilities - Leae liabilities			26.76	32.81
	Provisions			5.83	4.14
	Total non-current liabilities			32.59	36.95
(3)	Current liabilitie FinaciaJ liabilities
	- Lease liabilities			11.20	10.48
	- Trade paables
	- total outstading dues of - total outstading dues of	micro ad small enterprises creditors other tha micro and smaJI enterprises		1.23 67.36	3.61 43.38
	- Other fnacial liabilities			0.14	0.07
	Other current liabilities			38.34	41.20
	Provisions			3.44	1.69
	Curent ta liabilities (net)				20.54
	Total current liabilities			121.71	120.97
	Total liabilities (2+3)			154.30	157.92
	Total equity and liabilities (1+2+3)			2,125.94	2,195.35

==> picture [562 x 162] intentionally omitted <==

NURECA

www.nureca.com

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91-172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868

(Amount in INR million, unless otherwise stated)

		Statement of Standalone Cash Flow
			For	the
Sr. No.		Particulars	Half year ended JO Septem her 2022	Half year ended JO September 2021
			(Unaudited)		(Unaudited)
	Cash fows from operating activities
	(Loss)/proft befre tax fr the period Adjustments fr:		(86.66)		565.77
	Depreciation expense		11.90		4.48
	Income on unwinding of security deposits		(0.06)
	Unrealized freign exchage (gain)		(0.13)		(0.05)
	Finace costs		2.28		3.41
	Interest income		(21.45)		(31.84)
	Unrealized gain on mutual fnds		(6.83)		(1.73)
	Operating cash fows befre working capital changes		(100.95		540.04
	Working capital adjustments
	Decrease/(increase) in inventories		189.35		(223.05)
	(Increae) in trade receivales		(5.85)		(74.40)
	Increase in trade payables Decreae/(increae) in other assets		21.73 33.18		42.51 (44.00)
	(Decrease) in other current liabilities		(2.86)		(6.37)
	Increase in provisions		4.40		0.34
	Cash generated fom operating activities		139.00		235.07
	Incometaxpaid (net)		(36.24)		(123.85)
(A)	Net cash generated fom operating activities		102.76		111.22
	Cash fows from investing activities
	Purchae of propert, plat ad equipment		(1.42)		(15.18)
	Purchase oflntangible Assets under development				(4.19)
	Interest income received		9.89		24.16
	Investment in subsidiary		(I 7.50)		-
	Purchae of mutual fnds		(206.18)		(I 17.38)
	Sale of mutual fnds		18.50		-
	Unsecured Loa to subsidiaies		(13.40)		-
	Fixed deposits redeemed / (placed)		40.34		(35.61
(B)	Net cash used in investing activities		(169.77)		(148.20)
	Cash fows fom fnancing activities
	Pament of lease liabilities (including interest)		(7.07)		(3.37)
	Interest paid		(0.54)		(2.27)
	Repament of non-current borrowings		-		(7.79)
(C)	Repayment of curent borrowings (net) Net cash used in fnancing activities		17.61)		(1.46) (14.89
(A+B+C)	Net (decrease) in cash and cash equivalents		(74.62:		(51.87:
	Cah ad cash equivalents at the beginning of the yea		81.58		169.99
	Cah ad cash equivalents at the end of the period		6.96		118.12
	Components of cash and cash equivalents Balaces wth baks.
	- In current accounts		6.96		I 18.12
	Total cash and cash equivalents		6.96		118.12

==> picture [116 x 82] intentionally omitted <==

==> picture [574 x 87] intentionally omitted <==

NURECA

www.nureca.com

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited standalone financial results:

The above unaudited standalone financial results for the quarter and half year ended 30 September 2022 as reviewed by the Audit Committee, have been approved at the meetmg of the Board o Directors held on 11 November 2022. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visit the investor relation section of our website www.nureca.com and financials results at corporate section at www.bseindiacom andwww.nseindia.com.

• 2 The business of the Company falls within single line of business i.e. business of home healtcare and wellness products.

On 20 May 2022, the Company had invested INR 17.5 million on right issue basis in its wholly owned subsidiary i.e. Nureca Technologies Private Limited.

==> picture [535 x 96] intentionally omitted <==

----- Start of picture text -----

rd of Directors of
Nureca Limited
Saurabh Goyal
Place: Chandigarh (Managing Director)
Date: 11 November 2022 DIN: 00136037
----- End of picture text -----

==> picture [562 x 84] intentionally omitted <==

www.nureca.com

NURECA

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: ww .nureca.com Corporate Identification Number: L24304MB2016PLC320868

(Amount in INR million, unless otherwise stated)

	Statement of Unaudited Consolidated Financial	Statement of Unaudited Consolidated Financial	Results fr the quarter and half year ended	Results fr the quarter and half year ended	30 September 2022
			Quarter ended		Half year ended		Year ended
Sr.No.	Particulars	30 Sep ter her 2022 (Unaudited)	30 June 2022 (Unaudited)	30 September 2021 (Unaudited)	30 Sept em her 2022 (Unaudited)	30 September 2021 (Unaudited)	31 March 2022 (Audited)
I	Revenue fom operations	367.81	255.28	469.40	623.09	1,664.22	2,555.48
2	Other income	18.90	11.71	21.10	30.61	42.49	76.95
3	Total income (1+2)	386.71	266.99	490.50	653.70	1,706.71	2,632.43
4	Expenses
	Purchae of stock-in-trade	137.33	128.86	502.55	266.19	999.33	1,595.51
	Chages in inventories of stock-in-trade	136.83	41.95	(222.06)	178.78	(224.41)	(269.27)
	Employee benefts expense	50.03	42.79	22.91	92.82	48 06	99.14
	Finace costs	1.02	135	1.24	2.37	3.43	7.41
	Depreciation ad aortization expense	6.19	6.07	3.12	12.26	4.67	14.82
	Oter expenses	92.70	98.97	105.66	191.67	309.97	575.01
	Total expenses	424.10	319.99	413.42	744.09	1,141.05	2,022.62
5	(Loss)/proft befre income tax (3-4)	(37.39)	(53.00)	77.08	(90.39)	565.66	609.81
6	Tax expense
	- Current ta			22.17		149.68	155.70
	- Defrred ta (credit)/chage	(8.47)	(I 1.71)	0.57	(20.18)	(0.32}	4.51
7	Net (loss}/proft afer income tax (5-6)	(28.92	(41.29	54.34	(70.21'	416.30	449.60
8	Other comprehensive income(expense)
A	(i) Item that will not be reclassifed to proft or loss	0.48	0.48	0.07	0.96	0.10	1.90
	(ii) Income tax relating toitems that will notbe reclassifed to proft or loss	(0.12)	(0.12)	(0.02)	(0.24)	(0.03}	(0.48)
B	(i) Item that will be recla ifed to proft or loss	(0.01)	(0.02)	0.00	(0.03)	0.00	(0.01)
	(ii)Incometarelatingtoitemsthatwillbe reclassifed to proft or loss	-	-		-
	Total other comprehensive income for the	0.35	0.34	0.05	0.69	0.07	1.41
	period/year (net of tax)
9	Total comprehensive (loss)/income for the period/	(28.57)	(40.95)	54.39	(69.52)	416.37	451.01
	year(7+8)
10	(Loss)/earnings per share of Rs. 10 each
	- Basic ad diluted (in rpees) (not a ualized)	(2.89)	(4.13)	5.43	(7.02)	41.63	44.96
II	Paid-up equity share capital	100.00	100.00	100.00	100.00	100.00	100.00
	(Face value of share - Rs. IO each)
12	Reserve (excluding revaluation resere)						1,931.98
	See accompaying notes to the unaudited consolidated fnacial results

==> picture [134 x 84] intentionally omitted <==

==> picture [565 x 85] intentionally omitted <==

www.nureca.com

NURECA

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: ww .nureca.com Corporate Identification Number: L24304MHl016PLC320868

			(mount in IR million, unless otherise stated)	(mount in IR million, unless otherise stated)
		Statement of consolidated Assets and Liabilities
			As at
Sr.No.		Particulars	30 Septem her 2022	31 March 2022
			(Unaudited)	(Audited)
	Assets
	Non-current assets
	Proper, plat ad equipment		33.85	36.78
	Right-of-use assets		35.12	41.19
	Intangible assets		27.64	23.92
	Intagible a ets under development Finacia assets - Other fnacial assets Defred ta assets (net) Income ta a ets (net)		2.80 21.15 15.72	4.23 22.24 1.01
	Total non-current assets		136.28	129.37
(2)	Current assets
	Inventories		455.66	631.77
	Finacial assets
	- Investments		526.37	331.86
	- Trade receivables - Cash ad cash equivalents - Bank balaces other tha cah ad cah equivalents - Other fnacial assets		27.1 13.42 739.44 70.68	28.94 82.49 761.03 67.38
	Other current assets		140.73	158.46
	Total current assets		1,973.81	2,061.93
	Total assets (1+2)		2,110.09	2,191.30
(1)	Equity
	Equity shae capital		100.00	100.00
	Other equity		1,862.46	1,931.98
	Total equity		1,962.46	2,031.98
(2)	Non- current liabilities
	Finacial liabilities - Leae liabilities		26.76	32.81
	Provisions		5.94	4.13
	Total non-current liabilities		32.70	36.94
(3)	Current liabilities Finacial liabilities - Borowings - Leae liabilities		0.79 11.20	0.76 10.48
	- Trade payables
	- tota outstading dues of micro ad small enterprises - tota outstading dues of creditors other tha micro and small enterprises - Other fnacial liabilities		1.23 58.97 0.34	3.61 43.60 0.22
	Other current liabilities		38.88	41.44
	Provisions		3.52	1.69
	Curent ta liabilities (net)			20.58
	Total current liabilities		114.93	122.38
	Total liabilities (2+3)		147.63	159.32
	Total equity and liabilities (1+2+3)

L243()4r-!im20 6P-LC320868

www.nureca.com

NURECA

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: www.nureca.com Corporate Identification Number: L24304MI12016PLC320868

			(mount	in IR milon, unlss	otherise stated)
		Statement of consolidated Cash Flow
				For the
Sr. No.		Particulars	Half year ended Half year ended 30 Sept em her 202230 September 2021
				(Unaudited)	(Unaudited)
	Cash fows fom operating activities (Loss)lproft befre tax fr the period			(90.39)	565.66
	Adjustments fr:
	Depreciation expense			12.26	4.67
	Income on unwinding of security deposits			(0.06)	(0.02)
	Unrealized freign exchage (gain) Finace costs			(0.13) 2.37	(0.05) 3.43
	Interest income			(21.30)	(31.84)
	Unrealized gain on mutual fnds Operating cash fows befre working capital changes			(6.83) (104.08)	(1.13) 540.12
	Working capital adjustments Decreae/(increae) in inventories Decreae/(increae) in trade receivables Increase in trade paables Decreae/(increae) in other current assets (Decreae) in other fnacial liabilities			176.11 1.43 13.12 25.63 (0.07)	(222.38) (74.69) 42.77 (45.99) -
	(Decrease) in other current liabilities			(2.56)	(6.38)
	Increase in provisions			4.60	0.34
	Cash generated from operating activities			114.18	233.79
	Income tax paid (net)			(36.30)	(123.88)
(A)	Net cash generated fom operating activities			77.88	109.91
	Cash fows fom investing activities Purchase of propert, plat ad equipment Purchae of intagibles a et under development Purchae oflntangible Assets			(1.84) - (0.91)	(15.18) (4.19) -
	Interest income received			9.90	24.16
	Purchae of mutual fnds Sale of mutual fnds			(206.18) 18.51	(I 17.37) -
	Fixed deposits redeemed / (placed)			41.23	(35.61:
(B)	Net cash used in investing activities			(139.29)	(148.19)
	Cash flows fom fnancing activities Pament of lease liabilities (including interest)			(7.08)	(3.35)
(C)	Interest paid Repament of non-current borrowings Proceeds fom/(repayment) of current borrowings (net) Net cash used in fnancing activities			(0.58) - 0.03 17.63	(2.28) (7.79) (1.45) /14.87
(A+B+C)	Net (decrease) in cash and cash equivalents Efect of exchage rate fuctuations on cah & cah equivalents held in freign currency Cah ad cah equivalents at the beginning of the year Cah ad cash equivalents at the end of the period			(69.04) (0.03) 82.49 13.42	(53.15) 172.42 119.27
	Components of cash and cash equivalents Baaces with baks:
	- In current accounts			7.62	119.27
	- Fixed deposits with original maturity upto three months			5.80
	Total cash and cash equivalents			13.42	119.27
			� �	cP L11 �OJ
				*
				-

==> picture [561 x 83] intentionally omitted <==

NURECA -- -

www.nureca.com

NURECA LIMITED

Office Number 101, 1st Floor Udyog Bhavan Sonawala Lane, Goregaon (East), Mumbai - 400063, Maharashtra, India Tel: +91 -172-5292900, E-mail: cs@nureca.com, Website: ww .nureca.com Corporate Identification Number: L24304MH2016PLC320868

Notes to the unaudited consolidated financial results:

The above unaudited consolidated financial results for the quarter and half year ended 3Q September 2022 as reviewed by the Audit Committee, have been approved at the meeting of the Board o Directors held on 11 November 2022. The limited review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details, visi the investor relation section of our website www.nurecacom and financials results at corporate section at www.bseindia.com and www.nseindia.com.

==> picture [525 x 109] intentionally omitted <==

----- Start of picture text -----

2 The business of the Company falls within single line of business i.e. business of home healthcare and wellness products
For and on behalf of Board of Directors o
u ca Limited
Saurabh Goyal
Pl ace: Chandigarh (Managing Director)
Date: 11 November 2022 DIN : 00136037
----- End of picture text -----

==> picture [562 x 85] intentionally omitted <==

Chartered Accountants

BS R & Co. LLP

Unit No. A505 (A), Telephone: +91 172 664 4000 5th Floor, PlotNo.178-178A, Fax: +91 172 664 4004 Industrial & Business Park, Phase -1, Chandigarh-160002

Limited Review Report on unaudited standalone financial results of Nureca Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 01 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Nureca Limited ("the Company") for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

==> picture [90 x 26] intentionally omitted <==

Ankush Goel

Partner

New Delhi

11 November 2022

Membership No.: 505121 UDIN:22505121 BCVSSF7962

Registered Office:

BS R & Co. (a partnership firm with Registration No. BA61223) converted into 8 SR & Co LLP {a L1m1ted Uabi11ty Partnershrp with LLP Reg1strat1on No AAB-8181) with effect from October 14, 2013

14th Floor, Central 8 Wmg_ano North C Wing, N:esco IT Par1< 4, Neseo Center, Western Express Highway. Goregaon (EHt). Mumbai - 400063

Chartered Accountants

BS R & Co. LLP

Unit No. A505 (A), 5th Floor, Plot No.17B-178A, Industrial & Business Park, Phase -1, Chandigarh-160002

Telephone: +91 172 664 4000 Fax: +91 172 664 4004

Limited Review Report on unaudited consolidated financial results of Nureca Limited for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Nureca Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Nureca Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 September 2022 and year-to-date results for the period from 1 April 2022 to 30 September 2022 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting'' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

1. The Statement includes the results of the following entities :

2. a. Nureca Limited- Parent Company (incorporated in India)

3. b. Nureca INC- Subsidiary Company (incorporated in U.S.A.)

4. c. Nureca Healthcare Private Limited- Subsidiary Company (incorporated in India)

5. d. Nureca Technologies Private Limited, India- Subsidiary Company (incorporated in India)

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

A1

Registered Office:

B S R & Co. (a partnership finn with Registralion No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No MB-81B1) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wiog, Nesco IT Park 4, csco Center, Western Express Highway, GoragilCtt (East). Mumbai - .;00063

BS R & Co. LLP

1. The Statement includes the interim financial information of three subsidiaries which have not been reviewed, whose interim financial information reflect total assets (before consolidation adjustment) of Rs. 45.39 million as at 30 September 2022, total revenues (before consolidation adjustment) of Rs. 8.26 million and Rs. 8.26 million, total net (loss) after tax (before consolidation adjustment) of Rs. (1.03 million) and Rs. (3.65 million) and total comprehensive loss (before consolidation adjustment) of Rs. (1.03 million) and Rs. (3.65 million) for the quarter ended 30 September 2022 and for the period from 1 April 2022 to 30 September 2022, and cash flows (net) of Rs. 5.55 million for the period from 1 April 2022 to 30 September 2022, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B 5 R & Co. LLP

Chartered Accountants Firm's Registration No.:101248W/W-100022

==> picture [85 x 25] intentionally omitted <==

Ankush Goel

Partner

New Delhi

11 November 2022

Membership No.: 505121 UDIN:22505121 BCVTDL 7660

==> picture [217 x 54] intentionally omitted <==

Think.
Feel.
Create.

==> picture [13 x 13] intentionally omitted <==

==> picture [546 x 540] intentionally omitted <==

Earnings Presentation
November 2022

Disclaimer

ThePresentationistoprovidethegeneralbackgroundinformationabouttheCompany’s
activitiesasatthedateofthePresentation.Theinformationcontainedhereinisfor
generalinformationpurposesonlyandbasedonestimatesandshouldnotbeconsideredas
arecommendationthatanyinvestorshouldsubscribe/purchasethecompanyshares.The
Companymakesnorepresentationorwarranty,expressorimplied,asto,anddoesnot
acceptanyresponsibilityorliabilitywithrespectto,thefairness,accuracy,
completenessorcorrectnessofanyinformationcontainedherein.
Thispresentationmayincludecertain“forwardlookingstatements”.Thesestatementsare
basedoncurrentexpectations,forecastsandassumptionsthataresubjecttorisksand
uncertaintieswhichcouldcauseactualoutcomesandresultstodiffermateriallyfrom
thesestatements.Importantfactorsthatcouldcauseactualresultstodiffermaterially
fromourexpectationsinclude,amongstothers,generaleconomicandbusinessconditions
inIndiaandabroad,abilitytosuccessfullyimplementourstrategy,ourresearch&
developmentefforts,ourgrowth&expansionplansandtechnologicalchanges,changesin
theIndianandinternationalinterestrates,changeinlawsandregulationsthatapplyto
thehealthcareindustry,increasingcompetition,changesinpoliticalconditionsin
India.Neitherthecompany,noritsDirectorsandanyoftheaffiliatesoremployeehave
anyobligationtoupdateorotherwisereviseanyforward-lookingstatements.Thereaders
mayusetheirownjudgmentandareadvisedtomaketheirowncalculationsbeforedeciding
onanymatterbasedontheinformationgivenherein.
Nopartofthispresentationmaybereproduced,quotedorcirculatedwithoutprior
writtenapprovalfromNurecaLtd.

02

NURECA,
is a leading Digital
healthcare and wellness
Solutions provider

==> picture [42 x 44] intentionally omitted <==

C H R O N I C
D I S E A S E S

==> picture [43 x 42] intentionally omitted <==

L I F E S T Y L E
&  F I T N E S S

==> picture [43 x 43] intentionally omitted <==

O R T H O C A R E

==> picture [42 x 43] intentionally omitted <==

M O T H E R
&  B A B Y

Our
Focus
Areas

==> picture [44 x 46] intentionally omitted <==

N U T R I T I O N

2021

Listed On Stock
Exchanges

₹ 39 CR

Total Revenue For
Q2FY23

₹ (3) CR EBITDA For Q2FY23

03

Established Brands

==> picture [43 x 24] intentionally omitted <==

==> picture [51 x 14] intentionally omitted <==

==> picture [65 x 13] intentionally omitted <==

₹ 50 CR GMV For Q2FY23

50+

USFDA Approved
Products

₹ (3) CR PAT For Q2FY23

210+SKUS
Respiratory,
Physiotherapy,
Cardiac, Diabetes
And Mother & Child
Care

03

Our growing customer base

==> picture [508 x 396] intentionally omitted <==

----- Start of picture text -----

CUSTOMER BASE STEADY
(CUMULATIVE) [] IMPROVEMENT IN
( 0 0 0 ’ )
REPEAT CUSTOMER
Returning visitors to
our website
11,581
10,683
15%
8,021 12%
4,639
713
153%
FY19 FY20 FY21 FY22 FY23
CAGR
(as of
Sep'22) H1FY22 H1FY23
----- End of picture text -----*

STEADY IMPROVEMENT IN REPEAT CUSTOMER Returning visitors to our website 15% 12%

Our customer base has
grown exceptionally over
the last 4 years which is a
result of remarkable
quality of our products
that led to word-of-mouth
marketing by our loyal
customer base. Currently,
most of our products enjoy
4+ Star ratings out of 5-
star ratings  across e-
commerce platform.

At Nureca, we have a focused marketing
strategy to grow our brands and our
advertisement expenditure in the range
of 3-5% of our revenue which lower
compared to the Industry average.

*Gross Market Volume

04

Financial Updates

==> picture [361 x 179] intentionally omitted <==

----- Start of picture text -----

GMV
(INR mn)
3,403
2,994
2,285
1,281
790 841
63%
YoY
FY19 FY20 FY21 FY22 H1FY22 H1FY23
----- End of picture text -----

==> picture [412 x 8] intentionally omitted <==

==> picture [359 x 200] intentionally omitted <==

----- Start of picture text -----

Operating Revenue
(INR mn)
2,555
2,135
1,664
994
619 623
63%
YoY
FY19 FY20 FY21 FY22 H1FY22 H1FY23
----- End of picture text -----

 GMV of H1’FY23 stood at Rs. 841 mn as compared to Rs. 2285 Mn in H1’FY22, decrease of 63%

 Operating Revenue was Rs. 623 mn in H1’FY23 as compared to Rs. 1,664 in H1’FY22, decrease of 63%  Overall, demand has seen a dip in H1’FY23 as compared to the same period last year, which had seen a huge surge in demand due to Covid-19  Our Gross margins in H1’FY23 were impacted due to lower demand, inflation in input cost, currency fluctuation as well as inflationary pressure in other non-core costs such as packaging, transport, etc.  Our employee cost has increased as compared to the same quarter last year due to aggressive talent acquisition across the business functions and verticals majorly for app development and expansion of Offline distribution network.  Other expenses are lower in H1’FY23 by 38%, as the variable cost decreased in line with the top line.  Overall, EBITDA was Rs. (30) mn in Q2’FY23 and PAT stood at Rs. (29) mn

05

==> picture [588 x 58] intentionally omitted <==

----- Start of picture text -----

Key Performance Indicators
EBITDA & EBITDA MARGIN
EPS
----- End of picture text -----

==> picture [869 x 432] intentionally omitted <==

----- Start of picture text -----

(INR mn)
40%
644 664 34%
30% 574 30%
62
26% 45
42
20%
15%
10% 10%
9
91 98 0% 9
113% 117%
-10%YoY YoY
-12% -7
-76
-20% FY19 FY20 FY21 FY22 H1FY22 H1FY23
FY19 FY20 FY21 FY22 H1FY22 H1FY23
Return Ratios
PAT & PAT MARGIN
(INR mn) ROE ROCE
464 450 416
24% 180%
21%
17% 129%
10% 56% 57% 52% 67% 46% 61%
6% 25% 33%
-7% -9%
62 64
117%
FY19 FY20 FY21 FY22 H1FY22 H1FY23
YoY
-11%
-70
FY19 FY20 FY21 FY22 H1FY22 H1FY23 Note: ROCE derived on basis of average equity and average capital employed
----- End of picture text -----

06

–
Financials Income Statement

Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement	Financials– Income Statement
(INRmn)
Particulars																				% Q2'FY23 vs Q2'FY22
	articulars							**Q2'FY22 **		Q1'FY23				**Q2'FY23 **		% Q2'FY23 vs Q1'FY23				% Q2'FY23 vs Q2'FY22
	Revenue from operations							469				2	55	36	8		44%			-22%
	Other Income							21					12	1	9		61%			-10%
		Income
T	otal	R	evenue					491				2	67	38	7		45%			-21			%
																		5
	Cost	of	Goods Sol	d				280				1	71	27	4				61%			-2%
E	mpl	oy	ee benefits	ex	pense			23					43	5	0				17%			118%
	Other	ex	penses										99	9	3				-6%			-12%
								106
T	otal	E	xpenses					409				3	13	41	7				33%			2	%
E	BIT	DA						81				-	46	-3	0				34%			-137	%
F	inan	ce	Cost					1					1		1				-24%			-18%
	Depre	ci	ation					3					6		6				2%			98%
P	BT							77				-	53	-3	7				29%			-149	%
	Curre	nt	tax					22					-		-				-				-
	Deferred tax
													12						-28%
PAT								54		-41				-29		30%				-153%

07

New Product Launches

==> picture [12 x 11] intentionally omitted <==

- DR TRUST Orthopedic Heat belt 346

In the recently concluded quarter, we launched Orthopedic Heat Belt 346 under our Dr Trust Brand. This easy-to-use heating belt provides warming effects and relaxation to the affected body parts and reduces pain. It has an inbuilt dual thermostat plus 4 layers of insulation to ensure safety and comfort. Further, its soft and washable cover is easy to clean and maintain.

This universal size belt fits all and ensures a firm hold through a long velcro strap. It has an adjustable 3 remote-controlled temperature setting up to 85 °C and a 2.45 m extra-long connecting cable for the varied needs of each user. This is suitable for those dealing with backache, period cramps, sore muscles, stiff joints, or other body pain issues that make it difficult for them to carry out everyday activities.

==> picture [340 x 340] intentionally omitted <==

08

Smart Products Portfolio -

*Our devices are clinically accurate USFDA & CE Approved

==> picture [98 x 98] intentionally omitted <==

Body composition scales

==> picture [101 x 101] intentionally omitted <==

BP monitors

==> picture [41 x 96] intentionally omitted <==

==> picture [70 x 86] intentionally omitted <==

Glucometers ECG monitor

==> picture [105 x 123] intentionally omitted <==

==> picture [107 x 107] intentionally omitted <==

Smartwatches Pulse Oximeter

Health metrics captured from devices:

Weighing scale*

Glucometer*

BP Monitor*

Bone Mass
BMI & BMR  Systolic BPFasting
Subcutaneous FatDiastolic BPAfter Meal
Body Fat %  Pulse RateBefore Meal
Muscle Mass & RateAgeRandom
Protein MassHeightAge
Visceral Fat     Body weightHeight
Body Water % Body weight
Metabolic Age
Age
Height

Pulse Oximeter*

Smartwatches ECG monitor* - Health Monitoring -SPO2 - Electrocardiogram Body -Heart Rate Heart rhythm Temperature - Heartbeat rate SpO2 - Age Heart Rate - Height Blood Pressure - Body weight HRV & Stress Level - Tracking fitness with multisport mode

09

Our AI driven platform –

==> picture [436 x 228] intentionally omitted <==

==> picture [436 x 229] intentionally omitted <==

==> picture [436 x 228] intentionally omitted <==

==> picture [436 x 228] intentionally omitted <==

010

Our connected health solution -

Aggregate

Aunifiedapptotrackallthehealthmetricsandvitals
collectedfromvariousDrTrustdevices

Access

Consultspecialistsfromtophospitals,bookdiagnostics
andlabservices

Interact

Sharerealtimehealthdatawithdoctorsnutritionist
andhealthguardians

Engage

Personalisedrecipes,nutritionandworkoutvideos
targetedaroundusergoals

==> picture [285 x 436] intentionally omitted <==

011

- Holistic Solutions

On our smart healthcare platform, Dr Trust 360, we have a series of value-added features: Virtual Care & Telehealth

Dr Trust 360 now makes it easy to consult leading doctors at the
comfort and convenience of your home via a video call. Our
nutrition plans, combine behavioral psychology, technology, and
live nutritionists coaching, helping our users in their weight
management journey.

Health guardians

Add your health guardians so that they can be in the loop with
the progress you make. Your heath guardians shall receive
whatsappalerts at the right time when your readings are not
in range.

Track your daily calories & Nutritional Support

Add and track your daily meals with our nutrition database with over
1,00,000+ Indian and global food items. Set your daily calorie intake
goal and better understand your macro nutrient intake too. For better
health management, platform provides nutritional support to our users
with customised diet plan, calories tracking and dedicated
nutritionist to guide our users achieved better results

==> picture [78 x 154] intentionally omitted <==

==> picture [103 x 124] intentionally omitted <==

==> picture [89 x 175] intentionally omitted <==

012

==> picture [84 x 126] intentionally omitted <==

Holistic Solutions

On our smart healthcare platform, Dr Trust 360, we have a series of value-added features :

==> picture [86 x 145] intentionally omitted <==

==> picture [86 x 145] intentionally omitted <==

Measure health data

Dr Trust 360 now makes it easy to measure weight, blood pressure,
blood sugar, etc via DrTrust devices

==> picture [90 x 160] intentionally omitted <==

==> picture [93 x 160] intentionally omitted <==

Analyse

Dr Trust 360 platform now enables user to derive interactive
actionable insights & trends to better manage their health

==> picture [95 x 160] intentionally omitted <==

==> picture [95 x 160] intentionally omitted <==

Smart Sensei™ Technology

Enabling direct capture of vitals from non-connected devices
without any manual intervention

013

Holistic Solutions

During the quarter, we have added more value-added features:

==> picture [225 x 264] intentionally omitted <==

User Onboarding

Revamped onboarding
flow by reducing
complications and
personalizing it
further based on User’s
end goal.

==> picture [226 x 274] intentionally omitted <==

Home

The banner section on
the top now help
integrate the Dr Trust
store and also run
multiple campaigns
promoting our smart
diet plan.

==> picture [227 x 266] intentionally omitted <==

Nutrition UI

A new nutrition
logging UI is now
introduced to help
make food logging
into a better user
experience

014

- Nureca Technologies ISO 13485 and 9001 Certification

==> picture [307 x 415] intentionally omitted <==

NurecaTechnologiesPrivateLimited,aWholly
ownedsubsidiaryofNurecaLimited,hasobtained
ISO13485:2016andISO9001:2015certifications
fromnotifiedbodyIntertek,forNebulizersand
Bloodpressuremonitors.

These certifications represents another key milestone for the Company's globally certified made in India medical devices manufacturing site. It will open new avenues for the Company’s flagship brand “Dr Trust”, enabling to export these devices to many more countries. These certifications solidifies the Company’s commitment to quality and compliance in the world of health.

==> picture [183 x 245] intentionally omitted <==

==> picture [358 x 199] intentionally omitted <==

015

What Makes Nureca Different?

Product Quality

• •International standards quality and design of the products

Regulatory Compliance

• •Our products are manufactured to be safe, accurate, long-lasting and compliant to national and international regulations. Our chronic monitoring devices are USFDA approved .

==> picture [330 x 29] intentionally omitted <==

Wide product range

• •Nureca offers an entire bouquet of digital home healthcare devices

• Price-value proposition

• •Superior consumer price-value proposition with stringent quality control

• Brand Loyalty

• •Over the course of last 5 years, Nureca has generated a loyal customer base of over 8 million customers

Focused digital strategy

• •Emphasis on ‘Point of Sales’ (POS) marketing via online channels; Videos on digital shelf and YouTube channel; Presence across multiple digital media; Strong emphasis on search engine optimisation (SEO).

016

Business Outlook

• •Strong focus on connected devices for remote patient monitoring

ADDING PRODUCTS AND CATEGORIES

• •Create a pipeline of innovative healthcare and wellness products

• •A strong customer base for cross-selling of different products

OFFLINE EXPANSION

• •Increase tie-ups with modern retail brands, pharmacy chains, hospital chains and leading electronics chains.

• •Increase online and offline advertising

MARKETING

• •Increase influencer marketing

• •The Company plans to leverage data analytics and artificial intelligence for higher conversions

With the launch of our connected devices eco system, we will leverage data science capabilities to empower more people living with chronic and lifestyle diseases to live better and healthier lives. Our software will analyze clinical data and apply iterative insights to our user’s lifestyle to deliver a more personalized care experience. This will reinforce our theme of shifting India’s healthcare sector from curative to preventive and further from preventive to pre-diagnostics. We will be one step closer to our goal of making a positive impact on the lifestyle and health of our esteemed users and eventually enhance the longevity of their lives. We are working with various partners and building capabilities to provide all healthcare services on our Dr. Trust 360 platform with affordable subscription rate which will change our business model from being product driven company to services driven company.

==> picture [180 x 180] intentionally omitted <==

017

Shareholder Information

Shareholding as on 30[th] September 2022

Share Information as on 30[th] September 2022

==> picture [402 x 323] intentionally omitted <==

----- Start of picture text -----

Others
2%
Individuals
26%
FIs/Banks
1% Promoters
70%
(Shares
FII pledged –Nil)
2%
----- End of picture text -----

	NSE Ticker	NURECA
	BSE Ticker	543264
	IPO Listing Date	25th February 2021
	Market Cap (INR Cr)	890
	Share Price (INR)	890
	Shares Outstanding Industry	1,00,00,175 Healthcare

018

Thank. You.

INVESTOR RELATIONS AT NURECA

Gurvikram Singh cs@nureca.com

Office No. 101, Udyog Bhavan, Sonawala Lane, Goregaon East, Mumbai, - Maharashtra 400063 Drtrust.in Drtrust360.com

==> picture [612 x 540] intentionally omitted <==